Traitement du SARS-CoV-2 en pédiatrie : quelles évidences et quelle utilité ? [Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?]

Details

Ressource 1Download: RMS_Traitement du SARS-CoV-2 en pédiatrie.pdf (1297.37 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_9FD582ADE3EC
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Traitement du SARS-CoV-2 en pédiatrie : quelles évidences et quelle utilité ? [Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?]
Journal
Revue medicale suisse
Author(s)
Fougère Y., Rohr M., Vetter P., Wagner N.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
17/02/2021
Peer-reviewed
Oui
Volume
17
Number
726
Pages
344-348
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Although SARS-CoV-2 infects individuals of all ages, children show less severe symptoms. Nevertheless, the very rare COVID-19 severe cases in paediatrics require our full attention. Much research has been conducted and is still ongoing on effective treatments. On the antiviral front, no molecule has been proven effective yet and the results of several studies on the benefit of monoclonal antibodies and convalescent plasma are pending. On the side of immunomodulators, the benefit of steroids has been demonstrated for patients severely ill. Other molecules are being investigated. However, all these studies focused on adults and paediatric data are warranted.
Keywords
Adult, COVID-19/therapy, Child, Coronavirus Infections, Humans, Immunization, Passive, Pediatrics, SARS-CoV-2, COVID-19 Serotherapy
Pubmed
Create date
01/03/2021 14:39
Last modification date
05/12/2023 8:15
Usage data